This company has been marked as potentially delisted and may not be actively trading. Trillium Therapeutics (TRIL) News Today Add Compare Share Share Headlines Stock AnalysisBuy This Stock TRIL Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Ratio Therapeutics and TerraPower Isotopes Sign Supply Agreement for Actinium-225 For Targeted RadiotherapeuticsJune 20, 2025 | finance.yahoo.comTrillium Therapeutics Stock Price HistoryMay 26, 2025 | investing.comWhen You Look Back in 5 Years, You'll Wish You'd Bought This $2 Trillion Artificial Intelligence (AI) StockJuly 30, 2024 | finance.yahoo.comLeiomyosarcoma Drug Pipeline Report 2023 - ResearchAndMarkets.comNovember 10, 2023 | businesswire.comMirati Therapeutics Stock (NASDAQ:MRTX), Analyst Ratings, Price Targets, PredictionsNovember 8, 2023 | benzinga.comThe Global T-Cell therapy Market size is expected to reach $9.2 billion by 2030, rising at a market growth of 17.5% CAGR during the forecast periodJuly 31, 2023 | uk.finance.yahoo.comWHO Red Flags Punjab-Made Cough Syrup In Fresh Alert: 'Can Cause Even Death'April 25, 2023 | msn.comLeukemia Therapeutics Global Market Report 2023April 4, 2023 | uk.finance.yahoo.comRatio Therapeutics Announces Licensing Agreement for Investigational PET Imaging Agent with MerckMarch 28, 2023 | finance.yahoo.comFDA Grants Fast Track Designation to Tvardi Therapeutics’ TTI-101 for Hepatocellular CarcinomaOctober 19, 2022 | nz.finance.yahoo.comCardiff Oncology: 41% Loss In One Day For A Best-In-Class Colorectal Cancer TreatmentSeptember 14, 2022 | seekingalpha.comZentalis Pharmaceuticals Appoints Dr. Jan Skvarka to its Board of DirectorsSeptember 12, 2022 | nz.finance.yahoo.comPfizer: Deal For Global Blood Therapeutics Carries Risk - More M&A Is NeededAugust 17, 2022 | seekingalpha.com10 Psychedelics CEOs To Pay Attention To In 2022June 22, 2022 | markets.businessinsider.comPfizer and Moderna created life-saving vaccines. So why are their stocks crumbling?May 20, 2022 | edition.cnn.com3 Dividend Stocks That We'd Buy Without Any HesitationMarch 20, 2022 | nasdaq.comMindset Pharma CEO, James Lanthier, Issues Letter to ShareholdersMarch 17, 2022 | stockhouse.comNeonMind Biosciences Inc.: NeonMind to Open its Inaugural Specialty Mental Health Clinic in Mississauga, OntarioFebruary 17, 2022 | finanznachrichten.deCD47 Targeting Therapeutics Market Industry Trends and Global Forecasts, 2021-2035 - ResearchAndMarkets.comDecember 14, 2021 | au.finance.yahoo.com3 Firms Draw Up Pfizer's $6.7B Arena Pharmaceuticals BuyDecember 14, 2021 | law360.comTrillium Therapeutics (NASDAQ:TRIL) Lifted to "Buy" at Zacks Investment ResearchNovember 17, 2021 | marketbeat.comTrillium Therapeutics (NASDAQ:TRIL) Downgraded to "Hold" at BenchmarkNovember 17, 2021 | marketbeat.comTrillium Therapeutics (Nasdaq:TRIL) HeadlineTrading was temporarily halted for "TRIL" at 07:11 PM with a stated reason of "News pending."...November 17, 2021 | marketbeat.comIs Trillium Therapeutics Inc. (TRIL) A Good Stock To Buy?October 25, 2021 | finance.yahoo.comTrillium Therapeutics (NASDAQ:TRIL) Upgraded to "Buy" at Zacks Investment ResearchOctober 19, 2021 | marketbeat.com2 Top Healthcare Stocks That Could Be Bought Out in 2022October 16, 2021 | msn.comBRIEF-Trillium Therapeutics Inc Says Pfizer Voluntarily Withdrew Its Hart-Scott-Rodino Act Filing, And Expects To Re-File Such Form On Or About October 14October 13, 2021 | msn.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates GWB, KDMN, SIC, TRIL; Shareholders are Encouraged to Contact the FirmSeptember 22, 2021 | finance.yahoo.comSHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Trillium Therapeutics, Inc. - TRILSeptember 11, 2021 | finance.yahoo.comMoore Kuehn Encourages TRIL, OPA, HRC, and CXP Investors to Contact Law FirmSeptember 9, 2021 | benzinga.comSHAREHOLDER ALERT: WeissLaw LLP Reminds DSPG, ADTN, TRIL, and SIC Shareholders About Its Ongoing InvestigationsSeptember 7, 2021 | finance.yahoo.comWhy Investors Should Love Pfizer's Acquisition of TrilliumSeptember 4, 2021 | finance.yahoo.comAugust M&A roundup: Trillium's redemption and Reebok's $2.5B saleSeptember 1, 2021 | bizjournals.comForget Trillium Therapeutics Stock (TSX:TRIL): Buy These Pharma Stocks Instead!August 31, 2021 | ca.finance.yahoo.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Trillium Therapeutics, Inc. BuyoutAugust 24, 2021 | finance.yahoo.comTrillium Therapeutics (NASDAQ:TRIL) Downgraded by JMP Securities to "Market Perform"August 24, 2021 | marketbeat.comTRILLIUM THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Trillium Therapeutics Inc. - TRILAugust 23, 2021 | finance.yahoo.comChip shortage to worsen, Trillium pops 180% after Pfizer buyout, Coinbase reassures on stablecoinsAugust 23, 2021 | finance.yahoo.comTrillium Therapeutics shares soar on Pfizer’s $2.26B dealAugust 23, 2021 | msn.comPfizer To Buy Trillium Therapeutics For $18.50/Shr Cash - Quick FactsAugust 23, 2021 | nasdaq.comTrillium Therapeutics soars 200% after Pfizer inks deal to buy cancer-drug company for $2.3 billionAugust 23, 2021 | msn.comPfizer to buy cancer drug developer Trillium in $2.3 billion dealAugust 23, 2021 | finance.yahoo.comTrillium Therapeutics' stock nearly triples after buyout deal with Pfizer valued at $2.26 billionAugust 23, 2021 | finance.yahoo.comUPDATE 2-Pfizer to buy cancer drug developer Trillium in $2.3 bln dealAugust 23, 2021 | finance.yahoo.comTrillium Therapeutics Reports Second Quarter 2021 Operating and Financial ResultsAugust 13, 2021 | finance.yahoo.comTrillium Therapeutics Announces Dosing of First Patient in Phase 1b/2 Study of TTI-622 in Combination With Azacitidine in TP53-Mutated Acute Myeloid LeukemiaAugust 9, 2021 | finance.yahoo.com Get Trillium Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TRIL and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TRIL Media Mentions By Week TRIL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TRIL News Sentiment▼0.000.99▲Average Medical News Sentiment TRIL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TRIL Articles This Week▼00▲TRIL Articles Average Week Get the Latest News and Ratings for TRIL and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Trillium Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies MorphoSys News Calliditas Therapeutics AB (publ) News Zymeworks News MBX Biosciences News Aerovate Therapeutics News Cybin News Virios Therapeutics News OS Therapies News Eliem Therapeutics News Actinium Pharmaceuticals News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TRIL) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredWhat Are Some Strategies to Help Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Trillium Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Trillium Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access